Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer
Autor: | D. M. Zahm, Jan Budczies, M K Mehta, E. Weiss, Manfred Dietel, S. Loibl, Ralf Kronenwett, Silvia Darb-Esfahani, Thomas Karn, M. Gehrmann, Hans Bojar, Carsten Denkert, F Khandan, Beyhan Ataseven, Achim Rody, Jan C. Brase, G. von Minckwitz |
---|---|
Rok vydání: | 2012 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Receptor ErbB-2 Breast Neoplasms triple negative predictive factor breast cancer Breast cancer Cell Line Tumor Internal medicine Humans Medicine RNA Messenger skin and connective tissue diseases Molecular Diagnostics Triple-negative breast cancer Reverse Transcriptase Polymerase Chain Reaction business.industry Gene Expression Profiling thymosin beta 15 Estrogen Receptor alpha Thymosin medicine.disease Clinical trial Logistic Models Clinical Trials Phase III as Topic Immunology Female Thymosin beta 15a Receptors Progesterone business Estrogen receptor alpha hormones hormone substitutes and hormone antagonists Chemotherapy response neoadjuvant chemotherapy |
Zdroj: | British Journal of Cancer |
ISSN: | 1532-1827 0007-0920 |
DOI: | 10.1038/bjc.2012.475 |
Popis: | Background: Biomarkers predictive of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) of breast cancer are urgently needed. Methods: Using a training/validation approach for detection of predictive biomarkers in HER2-negative breast cancer, pre-therapeutic core biopsies from four independent cohorts were investigated: Gene array data were analysed in fresh frozen samples of two cohorts (n=86 and n=55). Quantitative reverse transcription polymerase chain reaction (qRT–PCR) was performed in formalin-fixed, paraffin-embedded (FFPE) samples from two neoadjuvant phase III trials (GeparTrio, n=212, and GeparQuattro, n=383). Results: A strong predictive capacity of thymosin beta 15 (TMSB15A) gene expression was evident in both fresh frozen cohorts (P |
Databáze: | OpenAIRE |
Externí odkaz: |